D000284

15 trials

Sponsors

Takeda Takashi, Harigae Hideo, Harigae Hideo, Taguchi Aya, Yamamoto Noboru

Conditions

Achondroplasia FGFR3, Short statureAdvance Non-Small Cell Lung Carcinoma Lung Cancer, Non-Small Lung Cancer, NSCLC, Met inhibitor, MET exon14 skipping mutationAdvanced urothelial carcinoma Advanced urothelial carcinomaCSPH in decompensated liver cirrhosis regardless of the etiology of chronic liver disease portal hypertension, liver cirrhosisChronic Thromboembolic Pulmonary Hypertension CTEPH, DOAC, warfarinChronic myelogenous leukemia in chronic phase CMLImmune-related adverse events, particularly colitis (irAE-colitis) Immune Checkpoint Inhibitor ColitisNocturia due to nocturnal polyuria nocturia, nocturnal polyuria

Phase 1

Meclizine Hydrochloride 2-week multi dose study.

Active, not recruitingJPRN-jRCT2041200114

Matsushita MasakiAchondroplasia FGFR3, Short stature

Start: 2021-04-14Target: 12Updated: 2025-07-18

The safety and efficacy of oral cancer vaccine B440

Active, not recruitingJPRN-jRCT2051220143

Teishima JunAdvanced urothelial carcinoma Advanced urothelial carcinoma

Start: 2023-01-19Target: 12Updated: 2025-07-18

RecruitingJPRN-jRCT2031240210

Yamamoto NoboruPatients with Unresectable advanced or recurrent solid tumors Solid tumor

Start: 2024-07-24Target: 42Updated: 2025-07-18

Phase 2

Phase 2, Open-label, Long-term study of the safety and efficacy of TM5614 in combination with tyrosine kinase inhibitors in chronic phase chronic myelogenous leukemia patients

Active, not recruitingJPRN-jRCT2031190071

Harigae HideoChronic myelogenous leukemia in chronic phase CML

Start: 2019-09-17Target: 35Updated: 2025-07-18

Assess the Anti-tumor Activity and Safety of Glumetinib in Patient With Advanced c-MET-positive Non-Small Cell Lung Cancer

Active, not recruitingJPRN-jRCT2051200072

Hayashi HidetoshiAdvance Non-Small Cell Lung Carcinoma Lung Cancer, Non-Small Lung Cancer, NSCLC, Met inhibitor, MET exon14 skipping mutation

Start: 2020-11-12Target: 24Updated: 2025-07-18

Invesigator-initiated phase 2 study to evaluate efficacy and safety of pyridoxamine in patients with premenstrual symdromes (PMS) and premenstrual dysphoric disorder (PMDD)

Active, not recruitingJPRN-jRCT2021200026

Takeda TakashiPremenstrual Syndrome and Premenstrual Dysphoric Disorder

Start: 2021-09-22Target: 105Updated: 2025-07-18

A Placebo-Controlled, Double-Blind, Phase II Physician-Initiated Trial of TM5614 in Patients with SARS-CoV-2 Pneumonia

Active, not recruitingJPRN-jRCT2021210006

Harigae Hideonovel coronavirus (SARS-CoV-2) pneumonia novel coronavirus pneumonia, novel coronavirus infection

Start: 2021-06-24Target: 100Updated: 2025-07-18

A study to test whether BI 685509 helps people with liver cirrhosis and high blood pressure in the portal vein (main vessel going to the liver) who had bleeding in the esophagus or fluid accumulation in the belly

Active, not recruitingJPRN-jRCT2031230564

Taguchi AyaCSPH in decompensated liver cirrhosis regardless of the etiology of chronic liver disease portal hypertension, liver cirrhosis

Start: 2024-01-31Target: 40Updated: 2025-07-18

A study of S095035 in adult participants with advanced or metastatic solid tumors with deletion of MTAP

RecruitingJPRN-jRCT2031240560

SADOU-DUBOURGNOUX Ameladvanced or metastatic solid tumors with homozygous deletion of MTAP 2-(4-amino-5H-pyrrolo-(3,2-d)pyrimidin-7-yl)-5-methylsulfanylmethylpyrrolidin-3,4-diol [Supplementary Concept]

Start: 2025-01-15Target: 27Updated: 2025-07-18

Efficacy and safety study of mesalazine in patients with immune checkpoint inhibitor-induced colitis

Active, not recruitingJPRN-jRCT2061240103

Yamashita KenImmune-related adverse events, particularly colitis (irAE-colitis) Immune Checkpoint Inhibitor Colitis

Start: 2025-06-02Target: 68Updated: 2025-07-18

Phase 3

Phase III Investigator-Initiated Trial to Investigate Safety and Efficacy of Edoxaban in Patients with Chronic Thromboembolic Pulmonary Hypertension

Active, not recruitingJPRN-jRCT2071200098

Abe KohtaroChronic Thromboembolic Pulmonary Hypertension CTEPH, DOAC, warfarin

Start: 2021-04-09Target: 74Updated: 2025-07-18

Preventive effect of ramelteon on delirium in ICU

Active, not recruitingJPRN-jRCTs041200112

Numaguchi AtushiPatients who need ICU management. intensive care

Start: 2021-03-11Target: 220Updated: 2025-07-18

Phase 3, randomized, double-blind study of the efficacy of TM5614 in combination with tyrosine kinase inhibitors in chronic phase chronic myelogenous leukemia patients

Active, not recruitingJPRN-jRCT2031220084

Harigae HideoChronic myelogenous leukemia in chronic phase CML

Start: 2022-07-29Target: 60Updated: 2025-07-18

Clinical Trial of Mexiletine for Spinal and Bulbar Muscular Atrophy

RecruitingJPRN-jRCT2041240174

Katsuno MasahisaSpinal and Bulbar Muscular Atrophy Spinal and Bulbar Muscular Atrophy

Start: 2025-02-28Target: 68Updated: 2025-07-18

Phase 4

Electroencephalography-based investigation of the effects of oral desmopressin on improving slow-wave sleep time in nocturnal polyuria patients

Active, not recruitingJPRN-jRCTs051190080

Torimoto KazumasaNocturia due to nocturnal polyuria nocturia, nocturnal polyuria

Start: 2020-01-07Target: 20Updated: 2025-07-18

Related Papers

Phase 1 study of B440, an oral <i>Bifidobacterium</i> -engineered WT1 cancer vaccine, in patients with metastatic urothelial cancer.

Journal of Clinical Oncology2025-05-28

A phase 1, first-in-human, open label, dose escalating study of B440, an oral cancer vaccine using a WT1-expressing <i>Bifidobacterium</i> , in patients with advanced urothelial cancer.

Journal of Clinical Oncology2025-02-10

Safety and efficacy of oral cancer vaccine B440 in patients with PD-1/PD-L1 inhibitor-resistant advanced urothelial cancer: a study protocol for a phase 1 multicenter, open-label, single-arm clinical trial.

2025-02-041 citations

A randomized double-blind placebo-controlled trial of an inhibitor of plasminogen activator inhibitor-1 (TM5614) in mild to moderate COVID-19.

2024-01-025 citations

Rationale, design, and methods of electroencephalography-based investigation of the effects of oral desmopressin on improving slow-wave sleep time in nocturnal polyuria patients (the DISTINCT study): protocol for a single-arm, open-label, single-assignment trial.

2020-07-111 citations